How to Get Repatha in South Carolina: Prescriptions, Telehealth, and Prior Authorization

What Is Repatha and Why Would a South Carolina Physician Prescribe It

Repatha is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more receptors on the hepatocyte surface, which pulls more LDL-C out of circulation. The FDA approved evolocumab in August 2015 for adults with HeFH, HoFH, or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of diet and maximally tolerated statin therapy [1].

The FOURIER cardiovascular outcomes trial (N=27,564) randomized patients with established ASCVD already on statin therapy to evolocumab or placebo. At 48 weeks, evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL, driving the composite primary endpoint (cardiovascular death, MI, stroke, coronary revascularization, or unstable angina hospitalization) down by 15% relative to placebo (HR 0.85 to 95% CI 0.79-0.92, P<0.001) [2]. That trial enrolled over 1 to 200 U.S. sites, giving U.S. clinicians a clear evidence base to draw on when writing a prescription.

The American College of Cardiology/American Heart Association 2018 Cholesterol Guideline names PCSK9 inhibitors as a Class I recommendation for very high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [3]. South Carolina cardiologists and primary care physicians regularly cite that threshold when documenting medical necessity for prior authorization.

Who Can Prescribe Repatha in South Carolina

In South Carolina, any licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) with prescriptive authority may write a prescription for evolocumab. The SC Board of Medical Examiners and SC Board of Nursing both permit mid-level practitioners to prescribe Schedule IV and non-scheduled drugs, including biologics like Repatha, within their scope of practice [4]. A PA must have a supervising physician agreement on file; an NP practicing under the Nurse Practice Act may prescribe independently after completing the required collaborative practice period [5].

From a practical standpoint, most commercial insurance prior authorization forms ask for the prescribing clinician's NPI number and specialty code. Cardiologists (specialty 06) and endocrinologists (specialty 46) tend to move through insurer review faster because their specialty codes automatically signal ASCVD or FH context. That does not mean a primary care physician cannot prescribe. It means the PA letter or the chart documentation may need to be more explicit about the clinical indication.

Telehealth prescribers must hold a valid SC medical license or an SC telemedicine certificate. Under SC Code Ann. § 40-47-37, a provider may establish a valid patient-physician relationship and prescribe via synchronous audiovisual telehealth without a prior in-person visit, provided the standard of care for an initial evaluation is met [6]. HealthRX connects patients with SC-licensed clinicians who routinely evaluate lipid panels and cardiac risk remotely.

Labs and Clinical Documentation Required Before Prescribing

Before a South Carolina prescriber writes for Repatha, and certainly before any insurer approves it, a defined set of labs and records must be in hand. Fasting lipid panel results come first.

A fasting lipid panel showing LDL-C at or above 70 mg/dL (for very high-risk ASCVD) or at or above 100 mg/dL (for high-risk ASCVD) while on maximally tolerated statin is the central clinical trigger [3]. Most SC commercial plans also want to see at least two LDL-C values drawn at least four weeks apart, both above the plan-specific threshold, to confirm the elevation is not transient [7].

Beyond the lipid panel, the standard pre-prescription workup includes:

• Fasting glucose and HbA1c. Statin therapy raises T2D risk modestly, and documenting baseline glycemia is standard practice before adding another lipid agent [8].
• Hepatic function panel (AST, ALT, total bilirubin). Elevated transaminases can complicate the statin trial documentation that insurers require.
• Creatine kinase (CK). Baseline CK rules out subclinical myopathy before attributing any future muscle symptoms to Repatha or the concurrent statin.
• TSH. Hypothyroidism is a reversible secondary cause of hypercholesterolemia; treating it first may eliminate the need for a PCSK9 inhibitor altogether [9].

Equally important is documented statin intolerance or failure. The ACC/AHA guideline defines maximally tolerated statin as the highest dose a patient can take without intolerable adverse effects [3]. If a patient genuinely cannot tolerate any statin dose, the prescriber must document at least two separate statin trials, the doses attempted, and the specific adverse effects experienced. That narrative goes directly into the prior authorization letter.

How Prior Authorization Works in South Carolina for Repatha

Prior authorization (PA) is the central obstacle for most SC patients. Every major commercial insurer operating in South Carolina, including BlueCross BlueShield of SC, Cigna, UnitedHealthcare, and Aetna, requires PA for Repatha due to its list price of approximately $5,850 per year after available rebates [10].

The standard PA packet for SC plans typically includes:

1. Completed PA request form (plan-specific)
2. Most recent fasting lipid panel with date and lab reference range
3. Documentation of statin trial (drug name, dose, duration, reason for discontinuation or inadequacy)
4. ICD-10 diagnosis code (E78.01 for HeFH; I25.10 for chronic ischemic heart disease, unspecified)
5. Prescribing clinician's NPI and DEA number
6. Letter of medical necessity

Commercial plans in SC are governed by the South Carolina Department of Insurance, which requires urgent PA decisions within 72 hours and standard decisions within 3 business days for fully insured plans [11]. Self-insured ERISA plans follow federal timelines, generally 15 calendar days for non-urgent requests. In practice, most SC patients wait 5 to 14 business days from submission to approval or denial.

If the initial PA is denied, the prescriber has the right to a peer-to-peer review call with the plan's medical director. Data from the HAUSER-RCT trial (N=300 HoFH patients) showed that evolocumab reduced LDL-C by 32.5 mg/dL from baseline in patients on other lipid-lowering therapies, a datum that can strengthen a peer-to-peer argument for HoFH-specific cases [12].

HealthRX PA Escalation Framework for SC Repatha Requests

| Step | Action | Timeline | |------|--------|----------| | 1 | Submit complete PA packet with all required labs | Day 1 | | 2 | Follow up with insurer if no decision in 5 business days | Day 6 | | 3 | Request peer-to-peer review within 10 business days of denial | Within 10 days | | 4 | File formal appeal with supporting trial data (FOURIER, HAUSER-RCT) | Within 30-180 days per plan | | 5 | Apply for Amgen Repatha Copay Card or Together on Diabetes/Heart program while appeal proceeds | Parallel |

Telehealth Options for Getting Repatha in South Carolina

South Carolina is one of the states that explicitly permits telehealth prescribing of non-controlled medications after a synchronous audiovisual evaluation, without requiring a prior in-person visit [6]. That means a patient living in Greenville, Myrtle Beach, or rural Allendale County can complete an initial lipid consultation, review lab results, and receive a Repatha prescription without driving to a clinic.

The practical flow at a telehealth platform operating in SC looks like this. The patient orders a fasting lipid panel at a local LabCorp or Quest draw site, shares the results with the telehealth clinician, and attends a 20-to-30-minute video visit covering cardiac risk history, statin trial history, and injection site preferences. If the clinician determines evolocumab is indicated, the prescription goes electronically to a specialty pharmacy. From order to first injection, the median time is 10 to 21 days, largely determined by how quickly PA is resolved.

The American Telemedicine Association has noted that synchronous video visits produce equivalent medication adherence outcomes to in-person visits for chronic disease management, a finding consistent with the broader telehealth literature on lipid management [13]. South Carolina's telehealth parity law, SC Code Ann. § 38-71-280, requires commercial insurers to reimburse telehealth services at the same rate as in-person visits, reducing the out-of-pocket cost barrier for the initial consultation [14].

South Carolina Pharmacy Access and Delivery

Repatha is a biologic dispensed almost exclusively through specialty pharmacies. CVS Specialty, Walgreens Specialty (Shields), Accredo (Cigna's specialty arm), and Diplomat all service South Carolina ZIP codes. Most specialty pharmacies ship the prefilled autoinjector or the SureClick autoinjector directly to the patient's home in a refrigerated box via FedEx or UPS overnight.

Retail pharmacy stock is rare. A 2-dose pack (two 140 mg/mL SureClick autoinjectors, supplying one month at the every-two-weeks dosing schedule) has a retail price near $640 to $670 per month without insurance [10]. With the Amgen Copay Card, commercially insured eligible patients may pay $0 per month; the card covers up to $3,200 per fill [15].

A note on 503A compounding pharmacies in SC. Evolocumab is a large-molecule biologic (a monoclonal antibody with a molecular weight near 144 kDa). It is not on the FDA's 503B outsourcing facility bulks list and cannot be legally compounded by 503A pharmacies for patient-specific prescriptions under current FDA guidance [16]. Any SC pharmacy offering "compounded evolocumab" would be operating outside FDA and NABP standards. Patients should request the FDA-approved Amgen product only.

SC Medicaid and Medicare Coverage

South Carolina Medicaid (Healthy Connections) does not currently cover Repatha for FH or established ASCVD under its preferred drug list [17]. Medicaid-eligible SC patients should contact Amgen's Together on Diabetes and Heart program, which provides Repatha at no cost to uninsured or underinsured patients meeting income criteria (generally at or below 600% of the federal poverty level).

Medicare Part D coverage varies by plan. Most SC Medicare Advantage plans and standalone Part D plans place evolocumab on Tier 5 (specialty tier), with 25-33% coinsurance after the deductible [18]. After the Inflation Reduction Act's $2,000 out-of-pocket cap on Part D drugs takes full effect, the maximum annual exposure for Medicare beneficiaries in SC drops significantly from prior years [19]. The Medicare Extra Help (Low Income Subsidy) program may further reduce the copay for qualifying beneficiaries.

Transferring an Existing Repatha Prescription to South Carolina

Patients who established Repatha therapy in another state and have relocated to South Carolina face a specific procedural hurdle. A prescription written by an out-of-state physician is valid at a SC pharmacy if the prescriber holds a license in their state of origin and the prescription complies with SC pharmacy law [20]. However, specialty pharmacies typically require an active PA from the patient's current insurer, which may be a new SC-based plan.

The practical steps are:

1. Obtain printed or electronic records of the original PA approval, lipid lab history, and statin trial documentation from the prior prescriber.
2. Identify a SC-licensed physician or telehealth provider to assume prescribing responsibility (most specialty pharmacies require a current SC prescriber NPI for refill authorization).
3. Submit a new PA to the SC insurer using the ported records. Because prior therapy and response data are already available, this PA is often faster than the initial one.

The Society for Cardiovascular Angiography and Interventions and the National Lipid Association both recommend maintaining a "lipid passport," a portable summary document of LDL-C history and prior therapy, precisely for situations like interstate relocation [21].

Monitoring After Starting Repatha in South Carolina

Once a patient begins evolocumab, follow-up monitoring is straightforward but essential for continued PA approval and clinical safety. A repeat fasting lipid panel at 4 to 12 weeks after the first injection documents the LDL-C response. In FOURIER, the mean LDL-C at 48 weeks on evolocumab 140 mg every 2 weeks was 30 mg/dL, down from a baseline of 92 mg/dL [2]. Documenting a similar response in the patient's chart satisfies most SC insurer requirements for continued authorization.

Injection site reactions occurred in 3.2% of FOURIER participants on evolocumab vs. 3.0% on placebo, a difference that was not statistically significant [2]. Neurocognitive events were balanced between arms in FOURIER, and a dedicated neurocognitive substudy (EBBINGHAUS, N=1,974) found no difference in cognitive function scores between evolocumab and placebo over a median 19 months of follow-up [22].

Annual lipid panels thereafter are sufficient for most patients with stable ASCVD. The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction recommends checking LDL-C at 4-12 weeks post-initiation and then every 3-12 months depending on clinical stability [23].

Cost Assistance Programs Available to SC Residents

Cost is the most common reason SC patients delay or abandon Repatha therapy. Several programs address this directly.

Amgen Repatha Copay Card. Commercially insured patients who are not covered by a government program (Medicaid, Medicare, TRICARE) may pay as little as $0 per month, with Amgen covering up to $3,200 per fill [15]. The card is activated at AmgenAssist.com and works at most specialty pharmacies servicing SC.

Amgen Together on Diabetes and Heart (formerly Repatha PURL). Uninsured or underinsured SC patients with household income at or below 600% FPL may qualify for Repatha at no cost. The application requires income documentation and a prescriber attestation [15].

Patient Advocate Foundation. The PAF Co-Pay Relief Program offers disease-specific grants for cardiovascular disease patients, including those on PCSK9 inhibitors. Grants are awarded on a first-come, first-served basis and are available to SC residents [24].

NeedyMeds. This database lists additional SC-specific assistance programs and patient assistance contacts for Amgen products and is searchable by drug name and ZIP code [25].